Adocia Announces Approval To Start A Phase IIa Clinical Study Of...
HinsBet's objective is to improve human insulin performance in a cost-effective way Phase IIa study will compare HinsBet to a fast-acting insulin analog and a regular human insulin in type 1 diabetic patients First Patient In planned for the first week of August Lyon, France, July 9th, 2014 - Adocia announced today that BfArM , the German ... (more)
The Motley Fool
MannKind Stock: Afrezza Approved at Last, But Will Sales Disappoint?
Approval is a major event for MannKind, but the company still needs a commercial partner and the approved label for Afrezza doesn't do the product/company any particular favors.
UPDATE 3-U.S. FDA approves MannKind's inhaled insulin, Afrezza
The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.
Medical News Today
Lilly announces detailed results from two Phase III studies testing...
Eli Lilly and Company has released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with a lower risk for hypoglycemia .1,2 Dulaglutide is an investigational glucagon-like peptide-1 receptor agonist being studied for ... (more)
Applied Clinical Trials
Lilly Announces Detailed Results from Two Phase III Studies Testing...
Results were presented at the 74th American Diabetes Association Scientific Sessions in San Francisco.